Pricing Log in Create free account
Saturday 17 October 2026 Export CING’s income statement to Excel — free account

Cingulate Inc.

CING Healthcare Biotechnology

In the quarter to June 2026, EPS grew 58.7% and free cash flow fell 24.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.33 0.06 −1.37%
Market cap
$63.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cingulate Inc. (CING) Business Profile

Updated before January 2025

Company Overview

Cingulate Inc. (CING) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for central nervous system (CNS) disorders. Founded in 2013 and headquartered in Kansas City, Kansas, Cingulate aims to address unmet medical needs by leveraging its proprietary Precision Timed Release (PTR™) drug delivery platform. The company was co-founded by Shane J. Schaffer, who serves as the Chairman and Chief Executive Officer, and Dr. Patrick Gallagher, the Chief Scientific Officer. Cingulate’s leadership team comprises seasoned professionals with extensive experience in pharmaceutical development, commercialization, and corporate strategy.

Core Business Segments

Cingulate operates primarily in the CNS therapeutic space, with a focus on developing medications for attention deficit/hyperactivity disorder (ADHD) and other related disorders. The company’s core business segments include:

ADHD Treatments

Cingulate’s flagship product candidates are designed to address the limitations of existing ADHD medications. These include:

  • CING-101 (CTx-1301): A once-daily, multi-release tablet designed to provide rapid onset and sustained efficacy throughout the day. CTx-1301 targets both children and adults with ADHD.
  • CING-102 (CTx-1302): Another once-daily ADHD treatment in development, aimed at providing tailored symptom control for patients with varying needs.

CNS Pipeline Expansion

Beyond ADHD, Cingulate is exploring the application of its PTR™ platform for other CNS disorders, including anxiety and depression. The company is actively conducting preclinical and clinical studies to expand its therapeutic portfolio.

Drug Delivery Technology

Cingulate’s proprietary PTR™ platform is a cornerstone of its business. This technology enables the precise timing of drug release, improving efficacy and patient compliance. The platform is adaptable to various therapeutic areas, offering potential for partnerships and licensing opportunities.

Business Model

Cingulate’s business model revolves around innovation in drug delivery and addressing unmet medical needs in CNS disorders. The company generates revenue through:

  1. Product Development: Developing and commercializing proprietary medications using the PTR™ platform.
  2. Licensing and Partnerships: Collaborating with other pharmaceutical companies to apply the PTR™ technology to their drug candidates.
  3. Market Expansion: Targeting global markets for ADHD and CNS treatments, leveraging regulatory approvals and strategic partnerships.

Cingulate’s approach integrates cutting-edge science with patient-centric solutions, aiming to improve quality of life for individuals with CNS disorders.

Strategic Direction

Cingulate’s strategic priorities include:

  • Advancing Clinical Trials: Completing Phase III trials for CTx-1301 and initiating pivotal studies for CTx-1302.
  • Regulatory Approvals: Securing FDA approval for its lead candidates and expanding into international markets.
  • Pipeline Diversification: Exploring new indications for the PTR™ platform, such as anxiety, depression, and bipolar disorder.
  • Sustainability Goals: Implementing environmentally friendly practices in drug manufacturing and packaging.
  • Strategic Partnerships: Collaborating with academic institutions and industry leaders to accelerate innovation and commercialization.

Competitive Landscape

Cingulate operates in a competitive market, facing challenges from established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Eli Lilly and Company: A leader in ADHD treatments with products like Strattera.
  • Takeda Pharmaceutical Company: Known for its ADHD medication Vyvanse.
  • Johnson & Johnson: Offers Concerta, a widely used ADHD treatment.
  • Supernus Pharmaceuticals: Focused on CNS disorders, including ADHD.

Cingulate differentiates itself through its PTR™ platform, which offers unique advantages in drug delivery and patient compliance.

Risk Factors

Cingulate faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: Delays or failures in obtaining FDA approval for its drug candidates.
  • Market Dependence: Heavy reliance on the success of CTx-1301 and CTx-1302.
  • Supply Chain Disruptions: Potential issues in sourcing raw materials or manufacturing delays.
  • Competition: Intense competition from established players and new entrants in the CNS market.
  • Financial Constraints: As a clinical-stage company, Cingulate relies on external funding and may face challenges in securing additional capital.

Recent Developments

Cingulate has made significant progress in recent years, including:

  • Clinical Milestones: Advancing Phase III trials for CTx-1301 and initiating studies for CTx-1302.
  • Partnerships: Collaborating with contract research organizations (CROs) to streamline clinical development.
  • Corporate Strategies: Expanding its leadership team and securing additional funding to support R&D activities.
  • Global Developments: Navigating the challenges posed by the COVID-19 pandemic, including supply chain disruptions and regulatory delays.

Investment Considerations

Strengths

  • Innovative Technology: The PTR™ platform offers a competitive edge in drug delivery.
  • Focused Pipeline: Targeting high-need areas like ADHD and CNS disorders.
  • Experienced Leadership: A seasoned team with a track record of success in pharmaceutical development.

Risks

  • Clinical and Regulatory Uncertainty: Dependence on successful trial outcomes and FDA approvals.
  • Financial Risks: Limited revenue streams as a clinical-stage company.
  • Market Competition: Facing established players with significant resources.

Conclusion

Cingulate Inc. is well-positioned to make a significant impact in the CNS therapeutic space. With its innovative PTR™ platform and a focused pipeline targeting ADHD and related disorders, the company has the potential to address unmet medical needs and improve patient outcomes. However, investors should carefully consider the risks associated with clinical-stage companies, including regulatory and financial uncertainties. As Cingulate advances its clinical programs and explores new therapeutic areas, it remains a promising player in the biopharmaceutical industry.